MY144781A - Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity - Google Patents

Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity

Info

Publication number
MY144781A
MY144781A MYPI20030651A MYPI20030651A MY144781A MY 144781 A MY144781 A MY 144781A MY PI20030651 A MYPI20030651 A MY PI20030651A MY PI20030651 A MYPI20030651 A MY PI20030651A MY 144781 A MY144781 A MY 144781A
Authority
MY
Malaysia
Prior art keywords
ambroxol
treatment
mouth
painful conditions
pharyngeal cavity
Prior art date
Application number
MYPI20030651A
Inventor
Esperester Dr Anke
Pschorn Dr Uwe
Vix Dr Jean-Michel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27740434&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY144781(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY144781A publication Critical patent/MY144781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE INVENTION RELATES TO THE USE OF AMBROXOL AND THE PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PAINFUL CONDITIONS IN THE ORAL AND PHARYNGEAL CAVITY.
MYPI20030651A 2002-02-27 2003-02-25 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity MY144781A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10208313A DE10208313A1 (en) 2002-02-27 2002-02-27 Ambroxol for the treatment of painful conditions in the mouth and throat

Publications (1)

Publication Number Publication Date
MY144781A true MY144781A (en) 2011-11-15

Family

ID=27740434

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20030651A MY144781A (en) 2002-02-27 2003-02-25 Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity

Country Status (21)

Country Link
EP (1) EP1480626A1 (en)
JP (1) JP2005518435A (en)
KR (1) KR20040084944A (en)
CN (1) CN1638749A (en)
AR (1) AR038698A1 (en)
AU (1) AU2003210345B2 (en)
BR (1) BR0308038A (en)
CA (1) CA2477105A1 (en)
DE (1) DE10208313A1 (en)
EC (1) ECSP045242A (en)
IS (1) IS7417A (en)
MX (1) MXPA04008220A (en)
MY (1) MY144781A (en)
PE (1) PE20030830A1 (en)
PL (1) PL371584A1 (en)
RU (1) RU2311176C2 (en)
TW (1) TW200306804A (en)
UA (1) UA86741C2 (en)
UY (1) UY27679A1 (en)
WO (1) WO2003072094A1 (en)
ZA (1) ZA200405635B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10332486A1 (en) * 2003-07-16 2005-02-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of acute pain
JP2005120063A (en) * 2003-10-14 2005-05-12 Boehringer Ingelheim Pharma Gmbh & Co Kg Ambroxol for treating inflammation at pharynx
ITMI20032462A1 (en) * 2003-12-16 2005-06-17 Advance Holdings Ltd METHOD TO PREPARE A CARAMEL CONTAINING AMBROXOLO AND THE CANDY SO OBTAINED
DE102004021992A1 (en) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topical preparation containing ambroxol
JP2007084471A (en) * 2005-09-21 2007-04-05 Sunstar Inc Composition for oral cavity and method of selecting product for oral cavity
EP2015761A4 (en) * 2006-03-29 2009-07-29 Naveh Pharma 1996 Ltd Methods and composition for treating sore throat
JP5765934B2 (en) * 2009-12-28 2015-08-19 サンスター株式会社 Oral composition
JP6171683B2 (en) * 2012-08-03 2017-08-02 大正製薬株式会社 Solid preparation
CN105769908B (en) * 2016-05-06 2019-03-01 湖北凤凰白云山药业有限公司 A kind of drug of preventing phlegm from forming and stopping coughing and preparation method thereof
CN115607531A (en) 2016-11-14 2023-01-17 王明武 Formulations for the treatment of ocular surface diseases
CN106727621A (en) * 2016-11-22 2017-05-31 郑州仁宏医药科技有限公司 A kind of Western medicine powder for treating toothache
JP6844394B2 (en) * 2017-04-14 2021-03-17 大正製薬株式会社 Solid composition
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138020B1 (en) * 1983-09-17 1992-06-03 Dr. Karl Thomae GmbH Anti-adhesive prophylactica and medicines containing a secretolytically active benzylamine derivative
DE3445226A1 (en) * 1983-12-14 1985-08-01 Reifenrath, Rainer Richard Otto, Dr.med., 7920 Heidenheim Pharmaceutical product for the treatment and prophylaxis of infections and of coughs and obstructive airway disorders
US5122540A (en) * 1986-02-28 1992-06-16 W. Keith R. Watson Method and composition for treating warts and throat soreness with DMSO and citric acid
DE4415553A1 (en) * 1994-05-03 1995-11-09 Behringwerke Ag Use of deoxyspergualin to prepare medicament
AU717764B2 (en) * 1996-05-02 2000-03-30 Taisho Pharmaceutical Co., Ltd. Suspension of sparingly water-soluble acidic drug
DE19933148A1 (en) * 1999-07-20 2001-01-25 Boehringer Ingelheim Int Lozenge containing ambroxol
JP2001151677A (en) * 1999-11-26 2001-06-05 Taisho Pharmaceut Co Ltd Composition for pharyngeal use
DE20102817U1 (en) * 2000-02-23 2001-06-07 Bolder Arzneimittel Gmbh Lozenges and chewing pills with cyclodextrin
US6391886B1 (en) * 2000-12-04 2002-05-21 The Procter & Gamble Company Oral compositions having improved consumer aesthetics

Also Published As

Publication number Publication date
DE10208313A1 (en) 2003-09-11
CA2477105A1 (en) 2003-09-04
AU2003210345B2 (en) 2009-01-29
CN1638749A (en) 2005-07-13
KR20040084944A (en) 2004-10-06
RU2004129284A (en) 2005-06-10
EP1480626A1 (en) 2004-12-01
UA86741C2 (en) 2009-05-25
PL371584A1 (en) 2005-06-27
UY27679A1 (en) 2003-09-30
IS7417A (en) 2004-08-19
AU2003210345A1 (en) 2003-09-09
ZA200405635B (en) 2005-05-31
AR038698A1 (en) 2005-01-26
TW200306804A (en) 2003-12-01
RU2311176C2 (en) 2007-11-27
BR0308038A (en) 2004-12-28
WO2003072094A1 (en) 2003-09-04
PE20030830A1 (en) 2003-10-31
ECSP045242A (en) 2004-09-28
MXPA04008220A (en) 2004-11-26
JP2005518435A (en) 2005-06-23

Similar Documents

Publication Publication Date Title
UA90518C2 (en) Pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, comprising a narcotic active ingredient and amine
MX2007004495A (en) Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline.
TW200637587A (en) Anti-caries oral care composition with xylitol
EP1469838A4 (en) Manufacture of oral dosage forms delivering both immediate release and sustained release drugs
DE60308647D1 (en) PHARMACEUTICAL FORM FOR MUCOSAL ADMINISTRATION
DE60327089D1 (en) SYSTEMS FOR MOVING AND / OR BACKING UP TISSUES IN THE UPPER AIRWAYS
UA92584C2 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MY144781A (en) Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
GEP20074047B (en) Pramipexole once-daily dosage form
DE60032691D1 (en) BRAUSETABLETTE FOR SUBLINGUALE, BUKKALE AND GINGIVALE ADMINISTRATION OF FENTANYL
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
NZ548215A (en) Effervescent oral opiate dosage form
TW200603787A (en) Topical preparations containing ambroxol
NO20071795L (en) Octenidine-containing tablets used for inflammatory diseases of the mouth and throat
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
SG148194A1 (en) Compositions for the treatment of affections of the oral cavity and upper respiratory tract
HUP0203844A2 (en) Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use
HRP20041092A2 (en) New pharmaceutical compositions containing filbanserin polymorph a
HUP0402178A2 (en) Pharmaceutical composition comprising a 5 hti receptor agonist
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
HUP0400495A2 (en) Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
HUP0102507A2 (en) Use of paroxetine in manufacture of a medicament for use in promoting smoking cessation or reduction or preventing smoking
MX2008002021A (en) Methods and compositions for soothing oral and nasal tissues.